skip to Main Content

Staphylococcus aureus skin infection model

The increasing rate of bacterial resistance creates a challenging environment for the development of therapies for bacterial infections. Bacterial skin infections are one of the leading manifestations of infectious disease in the world. Staphylococcus aureus—both Methicillin-resistant (MRSA) and Methicillin-Sensitive (MSSA) strains—is the leading cause of skin and soft tissue infections in the USA. It is the leading cause of hospital associated (HA) and community associated (CA) infections worldwide.

IBT Bioservices now offers a validated Staphylococcus aureus skin infection model for investigating pathogenesis of skin and soft tissue infections and to test the efficacy of antibacterial drug or vaccine candidates. In this BALB/c mouse model, the mice’s backs are shaved prior to intradermal (ID) infection with predetermines dose of S. aureus USA300. The treatment candidate is administered and the abscess lesion size (visible dermonecrosis) is measured once daily using digital calipers. Lesion area is calculated according to the following formula of an ellipse: A= Length/2 x Width/2 x π (approx. 3.14159).  Animals are monitored twice a day for up to 14 days to measure disease severity including weight loss and morbidity.

Figure 1. Mouse skin infection model. Area of lesion (A) and weight loss (B) measured daily for 14 days post infection with 1x107 CFU of S. aureus USA300. Model shows animals that received either treatment or placebo control intraperitoneally 4 hours prior to infection. Figure 1. Mouse skin infection model. Area of lesion (A) and weight loss (B) measured daily for 14 days post infection with 1x107 CFU of S. aureus USA300. Model shows animals that received either treatment or placebo control intraperitoneally 4 hours prior to infection.

The skin infection model figures above show results from animals that received a test treatment (blue) or a placebo control (black) via intraperitoneal (IP) injection 4 hours prior to infection. The area of lesion (A) and weight loss (B) are measured daily for 14 days post infection with 1×107 CFU of S. aureus USA300. 

At IBT Bioservices we offer a range of discovery tools and testing services to help progress your project toward your developmental milestone and secure your next round of funding. We share your goals of bringing new treatments to market. If you have an antimicrobial candidate you would like to test in this model, contact us

 

Back To Top
×Close search
Search

IBT Bioservices continues to conduct critical work as an essential business under the State of Maryland’s COVID-19 response directive. We have implemented a risk management plan and are continually monitoring the situation to ensure continuation of research according to public health services recommended best-practices for keeping our employees and the community safe. 

The IBT Bioservices team will continue to deliver high quality products and services for every project. If you have any questions contact us at Services@IBTBioservices.com